Hims & Hers Health, Inc. (NYSE:HIMS – Get Free Report) rose 5.2% during mid-day trading on Wednesday. The stock traded as high as $30.23 and last traded at $30.1970. Approximately 1,836,144 shares traded hands during mid-day trading, a decline of 92% from the average session volume of 23,752,195 shares. The stock had previously closed at $28.70.
Trending Headlines about Hims & Hers Health
Here are the key news stories impacting Hims & Hers Health this week:
- Neutral Sentiment: Multiple law firms issued substantially similar notices reminding investors who acquired HIMS securities between August 4, 2025, and July 29, 2026, that November 2, 2026, is the deadline to seek appointment as lead plaintiff. The repeated announcements largely amplify the same existing lawsuit rather than identify separate new legal actions. Kaplan Fox class action notice
- Negative Sentiment: The litigation creates potential financial, reputational and compliance risks for HIMS. Plaintiffs allege that the company made material misstatements or omissions about its privacy and billing practices, while the FTC’s complaint has already been associated with a reported stock decline of more than 14%. Investors may remain concerned about possible damages, legal expenses, regulatory remedies and disruption to the company’s operations. Hagens Berman class action announcement
Wall Street Analysts Forecast Growth
A number of brokerages recently issued reports on HIMS. Wall Street Zen upgraded Hims & Hers Health from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Barclays dropped their price target on Hims & Hers Health from $39.00 to $35.00 and set an “overweight” rating on the stock in a research note on Friday, August 21st. Weiss Ratings reissued a “sell (d)” rating on shares of Hims & Hers Health in a report on Friday, August 7th. JPMorgan Chase & Co. started coverage on Hims & Hers Health in a research note on Friday, September 11th. They issued a “neutral” rating and a $32.00 price objective for the company. Finally, Bank of America lifted their target price on Hims & Hers Health from $30.00 to $32.00 and gave the stock a “neutral” rating in a report on Tuesday, August 11th. Three analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Hims & Hers Health presently has an average rating of “Hold” and an average target price of $32.43.
Hims & Hers Health Trading Up 7.8%
The firm has a market cap of $7.22 billion, a PE ratio of -48.88 and a beta of 2.42. The company has a 50-day simple moving average of $29.37 and a 200 day simple moving average of $28.17. The company has a current ratio of 0.93, a quick ratio of 0.87 and a debt-to-equity ratio of 4.21.
Hims & Hers Health (NYSE:HIMS – Get Free Report) last issued its quarterly earnings data on Monday, August 10th. The company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.32). Hims & Hers Health had a negative return on equity of 6.51% and a negative net margin of 5.51%.The firm had revenue of $753.21 million during the quarter, compared to analyst estimates of $698.90 million. During the same quarter last year, the company posted $0.17 EPS. The company’s revenue was up 38.2% on a year-over-year basis. As a group, sell-side analysts forecast that Hims & Hers Health, Inc. will post -0.16 earnings per share for the current fiscal year.
Insiders Place Their Bets
In related news, CFO Oluyemi Okupe sold 29,277 shares of Hims & Hers Health stock in a transaction on Tuesday, September 22nd. The shares were sold at an average price of $29.95, for a total value of $876,846.15. Following the sale, the chief financial officer owned 236,527 shares of the company’s stock, valued at approximately $7,083,983.65. This trade represents a 11.01% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Deborah M. Autor sold 16,773 shares of the business’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $27.85, for a total transaction of $467,128.05. Following the completion of the sale, the insider directly owned 48,961 shares of the company’s stock, valued at approximately $1,363,563.85. The trade was a 25.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 128,684 shares of company stock valued at $3,731,869 over the last ninety days. 11.76% of the stock is owned by corporate insiders.
Institutional Trading of Hims & Hers Health
Several institutional investors have recently modified their holdings of the stock. QRG Capital Management Inc. purchased a new stake in shares of Hims & Hers Health during the second quarter worth about $248,000. Envestnet Portfolio Solutions Inc. lifted its stake in Hims & Hers Health by 46.9% in the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 32,469 shares of the company’s stock valued at $1,126,000 after buying an additional 10,366 shares in the last quarter. Bienville Capital Management LLC purchased a new position in Hims & Hers Health in the 2nd quarter valued at about $27,242,000. Engineers Gate Manager LP acquired a new stake in Hims & Hers Health in the 2nd quarter worth about $232,000. Finally, Integrated Wealth Concepts LLC acquired a new stake in Hims & Hers Health in the 2nd quarter worth about $147,000. Institutional investors and hedge funds own 63.52% of the company’s stock.
About Hims & Hers Health
Hims & Hers Health, Inc is a direct-to-consumer telehealth company that provides access to personalized healthcare through its online platforms, Hims and Hers. The company connects consumers with licensed healthcare professionals for virtual consultations, treatment plans and prescription medications where appropriate.
Its services address a range of common health and wellness needs, including sexual health, hair loss, skincare, mental health, weight management and primary care. Hims & Hers offers branded and generic treatments, over-the-counter products, supplements and personal-care products, with services designed for both men and women.
The company was founded in 2016, launched the Hims brand in 2017 and introduced the Hers brand in 2018.
Featured Stories
- Five stocks we like better than Hims & Hers Health
- 3 Healthcare Dividend Stocks Offering More Than Just Income
- AI Uncertainty Is Rising, But These 3 Chip ETFs Still Have Momentum
- Arhaus Has New Momentum—Could Other Furniture Stocks Be Next?
- Can Boxabl Turn Modular Homes Into AI Data Center Infrastructure?
Receive News & Ratings for Hims & Hers Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hims & Hers Health and related companies with MarketBeat.com's FREE daily email newsletter.
